Patient-reported feasibility of chest and thumb ECG after cryptogenic stroke in Sweden: an observational study

Peter Magnusson, Adam Lyren, Gustav Mattsson

ABSTRACT

Objectives The aim of this study was to assess the feasibility, based on a questionnaire, of the chest and thumb ECG system Coala Heart Monitor in patients who recently had a stroke.

Design Observational study.

Setting Two stroke units, Region Gävleborg, Sweden.

Participants and interventions This study, Transient ECG Assessment in Stroke Evaluation (TEASE), included patients who had a stroke between 2017 and 2019. Patients eligible for anticoagulation in the presence of atrial fibrillation were scheduled for 28 days monitoring.

Primary and secondary outcome measures The questionnaire regarding feasibility of monitoring included seven questions, using a 100 mm Visual Analogue Scale which covered overall satisfaction, technical feasibility, remember to monitor, physical application, feeling of security, help from others and recommendation to others. A lower score indicated better outcome.

Results The prespecified number of 100 patients underwent the monitoring and 83 out of the 97 alive patients returned the questionnaire (response rate 85.6%). The median age was 69.5 years, mean CHA2DS2-VASc score was 4.4±1.3 points and 59.0% were men (n=49). The median time from index stroke to start of monitoring was 7.0 days. Patients performed on average 90.1%±15.0% of scheduled ECG-transmissions. In all seven questions, the median score ranged from 4 to 8. The vast majority reported acceptable outcomes, that is, the 95th percentile ranged from 30 to 54. There was no significant difference between men and women with regard to any of the seven questions (p values ranging from 0.117 to 0.849). Two of the seven outcome scores correlated significantly to patient age (Spearman’s r=−0.238 and r=−0.308, and p values 0.031 and 0.005 for ‘overall satisfaction’ and ‘remember to monitor’, respectively).

Conclusion In stroke survivors, chest and thumb ECG two times per day over a period of 4 weeks is feasible from a patient’s perspective. The Coala Heart Monitor provides a valuable and convenient tool for monitoring after stroke.

Trial registration number NCT03301662.

INTRODUCTION

Atrial fibrillation (AF) is the most common arrhythmia, which will affect a quarter of the general population over the course of their lifetime.1 The same proportion, a quarter, will suffer from a stroke of any cause.2 In fact, the risk of ischaemic stroke quadruples with the same risk of embolisation.10–12 Silent episodes, approximately one-third of all AF, are especially common among the elderly. As a consequence, this warrants increased attention and resources to better diagnose AF. Stroke survivors should be a prioritised group for extended AF detection because of the risk of recurrence.13 This approach is endorsed by guidelines, but the monitoring tool, timing and duration remains to be established.14 15

Technological advancements, often connected with smartphones, have emerged as options beyond conventional 12-lead ECG and Holter monitoring.16

Insertable cardiac monitors in cryptogenic stroke provide long-term continuous...
monitoring, but this invasive strategy is seldom used in routine care because it requires considerable resources and involves high upfront costs, although insertable monitors have been deemed cost effective.\textsuperscript{17, 18} Alternative strategies include monitoring using continuous ECG in the hospital ward, repeated ECGs, Holter monitoring, external event or loop recorders, long-term monitoring using patches and handheld devices.

In the Transient ECG Assessment in Stroke Evaluation (TEASE) study\textsuperscript{19} it was decided to use the Coala Heart Monitor. This newly developed device with proven detection algorithms, similar to Zenicor, uses a smartphone application and seems to be a promising alternative, but feasibility remains to be studied.\textsuperscript{20} In the prospective observational TEASE trial, we evaluated the patient-reported feasibility of the device system. The aim of this paper is to describe the feasibility, based on a questionnaire, of the Coala Heart Monitor in patients who recently had a stroke.

METHODS
Setting and selection
Patients with a clinically confirmed diagnosis of ischaemic stroke were recruited consecutively from the stroke units in Gävle and Hudiksvall in Sweden between October 2017 and October 2019. The predefined number of participants was 100 who underwent the monitoring per protocol.

Inclusion and exclusion
Adult patients with an unequivocal diagnosis of ischaemic cryptogenic stroke were eligible for the study. Patients who had a transient ischemic attack (TIA) were not included, because this diagnosis is often uncertain due to being based solely on patient history.

Patients must be indicated for NOAC in the presence of newly detected AF. A history of atrial arrhythmia or the presence of an implantable cardiac device were exclusion criteria as were indications for permanent anticoagulation for reasons other than AF, that is, venous thrombosis and mechanical heart valve.

Stroke definition and evaluation
Cryptogenic stroke is defined as cerebral ischaemia of unknown aetiology, that is, not attributable to a source of cardiac embolism, large artery atherosclerosis or small artery disease despite a standard vascular, cardiac and serologic evaluation. Patients were evaluated with a carefully taken patient history, physical examination, routine laboratory tests and standard evaluation using 12-lead ECG, 24-hour Holter, carotid Doppler ultrasonography and/or computed tomography (CT) angiography, CT and, when applicable, magnetic resonance imaging, echocardiography or transesophageal echocardiography, as well as extended coagulation tests.

Chest and thumb ECG
Each patient was scheduled to use the Coala Life Monitor for 28 consecutive days.

Patients were requested to apply the chest and thumb ECG monitor device two times per day, around 08:00 with an interval of 2 hours before and after, that is, at 06:00–10:00 and again at 18:00–22:00. Patients were asked to use the chest and thumb ECG monitor device two times per day, at 06:00 and 22:00. Monitoring was planned to begin as soon as possible after the stroke diagnosis. Each recording was stored in a web-based application accessible to the investigators.

The Coala Heart Monitor
The Coala Heart Monitor is a handheld two-lead ECG recording device with a high sampling rate that in addition to thumb ECGs can also provide chest ECGs, which could allow for better discrimination of arrhythmias by more discernible atrial signals. The interpretation is based on pattern recognition algorithms, including AF detection based on RR dispersion and atrial signals. The device is connected wirelessly via Bluetooth connectivity to a smartphone. The user can view the interpretation on the smartphone and store PDFs of the tracings. The tracings are stored in the portal accessible to the healthcare provider. Messages to the patient can also be viewed directly on the app. There is also a feature that allows users to add a special heart report service to their smartphone to discuss their ECG recordings with trained nurses, but in our study, we did not use this option. These features allow a single centralised and highly specialised healthcare function to provide first-line primary cardiac healthcare coverage for a large and geographically spread-out population, which can be very advantageous in for a post-stroke population.

The questionnaire
The questionnaire regarding feasibility of monitoring consists of seven questions with the same structure, all

2. How was the technical feasibility of the chest- and thumb ECG?

![Very Easy](image1) ![Very Difficult](image2)
using a 100 mm Visual Analogue Scale (VAS) with words and pictures at each end (see figure 1 and online supplemental file). A lower score indicates better outcome. The questions are as follows:

1. Overall, what do you think about using the chest and thumb ECG? (Very satisfied, very dissatisfied)
2. How was the technical feasibility of the chest and thumb ECG? (Very easy, very difficult)
3. Did you remember to use the chest and thumb ECG as scheduled? (Always, never)
4. How was it physically to apply the chest and thumb ECG? (Very easy, very difficult)
5. Did the ECG monitoring affect your feeling of security? (Much more secure, much less secure)
6. Did you need help from others to perform the ECG monitoring? (Never needed help, always needed help)
7. Would you recommend other stroke patients use the chest and thumb ECG monitoring? (Strongly, not at all)

The following stroke symptoms were listed and the patient was asked to select a one-word descriptor (severe, moderate, mild, none) for each:

► Slurred speech.
► Impaired language comprehension.
► Arm weakness.
► Leg weakness.
► Impaired sensation.
► Memory problem.
► Fatigue.

Statistics

Numeric data are reported as frequencies, percentages, IQRs, percentiles and means, including SD. Differences in VAS results between subgroups were performed using the Mann-Whitney U test. Correlations between continuous variables were assessed using Spearman’s coefficients. Categorical variables were examined using Fisher’s exact test. A two-sided p value of <0.05 was defined as statistical significance. The data were first recorded in Excel 2010 (Microsoft Corporation) and subsequently, imported into SPSS V.25 (IBM).

Patient and public involvement

No patient involved.

RESULTS

A total of 83 questionnaires were returned and analysed. The age of the participants ranged from 27.6 to 86.4 years, with a median age of 69.5 years (IQR: 62.9–75.0) and the mean age was 67.6±11.1 years. The majority was man (n=49; 59.0%). The mean age was similar between men and women (66.7±9.9 vs 68.8±12.7 years; p=0.396).

The median time from index stroke to start of monitoring was 7.0 days (IQR 3.0–13.0 days). Patients performed on average 90.1%±15.0% of scheduled transmissions.

At baseline, the mean CHA2DS2- VASc score was 4.4±1.3 points. Since stroke was an inclusion criterion, all patients had at least 2 points per se and no patient had 8 or 9 points. The characteristics of the cohort at baseline are summarised in table 1. As part of the questionnaire, patients scored remaining stroke symptoms, which is reported in table 2. The distribution of score is summarised in table 3.

Analysis of non-response

Among the 111 patients who consented to participate, 11 dropped out because of cognitive and/or physical impairment, which made them unable to handle the technology or they did not wish to participate. Among the 100 participants who completed the chest and thumb ECG monitoring, none died during the ECG monitoring period, but three patients died before the time of the survey. Among the eligible patients, the reasons for not taking the survey were cognitive/physical impairment in nine patients and unknown in five patients, who were unavailable despite two written reminders and follow-up by phone. Thus, the response rate was 85.6% (83 out of 97 alive patients).

Table 1 Patient characteristics at baseline

| All (%) |
|-------------------------|
| Patients | 83 (100) |
| Mean age (years) | 67.6±11.1 |
| Median time from index stroke to inclusion (days) | 7.0 (IQR 3.0–13.0) |
| Congestive heart failure | 1 (1.2) |
| Hypertension | 64 (77.1) |
| Age ≥75 years | 20 (24.1) |
| Diabetes mellitus | 13 (15.7) |
| Stroke | 83 (100.0) |
| Vascular disease | 14 (16.9) |
| Age 65–74 years | 32 (38.6) |
| Sex category (female) | 34 (41.0) |

CHA2DS2-VASc score

| Mean total score |
|------------------|
| 0 point | 0 (0.0) |
| 1 point | 0 (0.0) |
| 2 points | 5 (6.0) |
| 3 points | 19 (22.9) |
| 4 points | 19 (22.9) |
| 5 points | 24 (28.9) |
| 6 points | 12 (14.5) |
| 7 points | 4 (4.8) |
| 8 points | 0 (0.0) |
| 9 points | 0 (0.0) |

Data presented as frequencies (percentage in parenthesis)
Outcome

Overall, patients reported very favourable experiences with Coala Heart Monitor. In all seven questions, the distribution was heavily skewed to the right (figure 2). The median score ranged from 4 to 8. The vast majority reported acceptable outcomes, that is, the 95th percentile ranged from 30 to 54.

There was no significant difference using Mann-Whitney U test between men and women with regard to any of the seven questions (p values ranging from 0.117 to 0.849).

Correlations

Two of the seven outcome scores correlated significantly to patient age (Spearman’s r=−0.238 and r=−0.308, and p values 0.031 and 0.005 for ‘Overall satisfaction’ and ‘Remember to monitor’, respectively). The other five outcome score did not correlate significantly to patient age (Spearman’s r ranging between −0.073 and −0.147, all p values ≥0.185).

DISCUSSION

Among patients who underwent chest and thumb ECG evaluation after stroke, the Coala Life Monitor demonstrated excellent feasibility over the 1 month period of two times per day monitoring.

All seven domains of patient experience that were evaluated by the questionnaire consistently showed a highly advantageous profile. These beneficial findings were seen despite advanced age and included both sexes. Obviously, patients who had a recent stroke are highly motivated to undergo extended evaluation. Nevertheless, the Coala Life Monitor is successful in providing a feasible tool for stroke survivors.

There is very limited self-reported feasibility information from other studies with handheld devices.

Handheld ECG after stroke

In another Swedish study of patients who had a stroke/TIA, using the Zenicor device 116 patients were enrolled but exclusion rates were high: 10 had cognitive impairment, 8...
were unwilling to participate and 7 were unable to handle the device.²¹

In a Danish study using the Zenicor device, it was reported that 21.0% (314/1498) of patients were not eligible due to cognitive or physical impairment.²²

In the largest study (n=284) of stroke patients using a dry-electrode belt around the chest (Cardiac Bio-Systems) and an event recorder (Er910AF Cardiac Event Monitor, Braemar), 82.0% completed the monitoring.²³

In a retrospective analysis of handheld ECG devices with a smartphone app (Zenicor) in a Swedish setting of routine care, 116 patients were eligible for 3 weeks of screening after stroke/TIA. In this pragmatic trial, five patients were non-compliant due to misunderstanding, five were unable to complete the screening due to technical problems and three for other causes.²⁴

A retrospective analysis of Zion-patch applications in patients who had a stroke/TIA showed high compliance (98.7%) during a median wearing time of 13.0 days.²⁵

**Handheld ECG in screening**

The thumb ECG has been used in screening programmes in several settings.¹⁶

In the StrokeStop I study, a total of 80 149 tracings were recorded using the Zenicor thumb ECG system; tracings were obtained from 3209 patients aged 75 or 76 years.²⁶

In the REHEARSE-AF study, an AliveCor Kardia monitor attached to a WiFi-enabled iPod was used in 500 elderly patients (72.6±5.4 years) with a mean CHA₂DS₂-VASc score 3.0; only 6.5% had a prior stroke/TIA.²⁷ The study duration was 52 weeks. As part of the study, a survey with a 5-point Likert scale was used. The vast majority were ‘not at all’ or only ‘slightly’ anxious about using the device: patients reported that they were ‘not at all’ restricted by the device; and the respondents said generally they were ‘extremely satisfied’ or ‘very satisfied’ with the use of the device.

A population-based study of 65 year olds with a CHA₂DS₂-VASc score ≥2 using the Zenicor device for 14 days screened 1601 subjects for participation, of whom 91 declined participation or failed to respond.²⁸

**Single-point studies**

In another study using a point-of-care screening for 60s (n=772; mean age 65.2±15.4; CHA₂DS₂-VASc≥2 in 75.7%) using the same device, the AliveCor Kardia monitor, the authors concluded that the screening provided collateral benefit in the form of patient and caregiver education. Participants were quite satisfied with the screening, and 90.6% agreed with the statement that they learnt more about AF.²⁹ Another single-point study shows feasibility in a national screening programme in Belgium.³⁰

**Miscellaneous monitoring systems**

Activity monitors, for example, smartwatches, often record heart rate by photoplethysmography and are promising for AF detection when supplemented with sophisticated learning algorithms, but they still do
not produce diagnostic ECGs and if abnormalities are detected, further confirmation with an ECG is required. These consumer-oriented products need validation; nevertheless, it is hoped that they may promote and spur innovation in accurately detecting AF and handling large amounts of data with automatic interpretation or at least efficient sorting functions. In a large-scale study, a smartwatch-based (Apple Watch) irregular pulse notification algorithm identified possible AF; this was followed by a telemedicine visit and an ECG patch was mailed to the participant. This patch had to be worn for up to 7 days; 34% of rhythms were classified as AF and 84% were concordant with AF. Because the guidelines mandate ECG for the diagnosis of AF, handheld devices offer the advantage of providing a verifiable ECG tracing. Thus, it is a preferred screening tool. Smartwatches capable of producing ECGs have been developed, but need further validation before they can be used in healthcare settings. Handheld devices are more accurate than pulse palpation; the sensitivity is 94%–99% and the specificity 92%–97%. The role of handheld devices as part of AF detection, both in primary and secondary prevention, is likely to increase in importance.16

**Future perspectives**

Guidelines already allow for prolonged ECG monitoring: ‘in patients who had a stroke, additional ECG monitoring by long-term noninvasive or implanted loop recorders should be considered to document silent AF’ (class IIa recommendation, level of evidence B). The diagnostic yield based on randomised controlled trial and observational trials is high; the number needed to screen=8–14 and depends on the method and follow-up time. Large-scale, pragmatic trials in different settings would be beneficial in order to study subgroups and finally standardise healthcare guidelines. In addition, the spur of technical advancement in ECG monitoring should be welcomed as an integral part of research and development projects.

Patient-led organisations may play an important role to engage policy-makers. Furthermore, close collaborations between different stakeholders are necessary to enhance innovation and implementation to provide structured care in a personalised medical approach in the field of ECG monitoring.

**CONCLUSION**

In stroke survivors, chest and thumb ECG two times per day over a period of 4 weeks is feasible from a patient’s perspective. The Coala Heart Monitor provides a valuable and convenient tool for monitoring after stroke.

**Acknowledgements**

The authors acknowledge editing by Jo Ann LeQuang of LeQ Medical who reviewed the manuscript for American English. Adrian Kling, Titti Lundgren, Ulf Tossman, Magnus Samuelsson and Philip Siberg from Coala Life are acknowledged for support regarding the Coala Life Monitor. The authors also wish to thank the staff at the stroke unit in Gävle and Hudiksvall for their participation in the study.

**Contributors**

PM contributed to idea, design, data collection, analyses and interpretation, administration, supervision, project management and writing of the manuscript. AL involved in data collection and critical revision of the manuscript. GM contributed to study design, data collection, analyses and interpretation, administration, project co-management and critical revision of the manuscript.

**Funding**

Region Gävleborg 20171001 funded this research project and Coala Life 20181006 provided free product Coala Heart Monitor during the study period.

**Competing interests**

The project received free product from Coala Life. Outside this project: PM has received speaker fees or grants from Abbott, Alynalam, Bayer, AstraZeneca, Boehringer-Ingelheim, Internetmedicin, Lilly, MSD, Novo Nordisk, Octopus Medical, Orion Pharma, Pfizer, Vifor Pharma and Zoll. AL has received speaker fees from Pfizer. GM has received speakers fee from Alynalam, MSD and Internetmedicin.

**Patient consent for publication**

Not required.

**Ethics approval**

The Regional Ethical Committee in Uppsala approved the study on 20 September 2017 (protocol number 2017/321). Patients consented to participation after oral and written information by any of the investigators.

**Provenance and peer review**

Not commissioned; externally peer reviewed.

**Data availability statement**

Data are available upon reasonable request. No additional data sharing available.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines,
References

1. Lloyd-Jones DM, Wang TJ, Leip EP, et al. Lifetime risk for development of atrial fibrillation: the Framingham heart study. Circulation 2004;110:1042–6.

2. GBD 2016 Lifetime Risk of Stroke Collaborators, Feigin VL, Nguyen G, et al. Global, regional, and Country-Specific lifetime risks of stroke, 1990 and 2016. N Engl J Med 2018;379:2429–37.

3. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke 1991;22:983–8.

4. Kishore A, Vail A, Majid A, et al. Detection of atrial fibrillation after ischemic stroke or transient ischemic attack: a systematic review and meta-analysis. Stroke 2014;45:520–6.

5. Lin H-J, Wolf PA, Kelly-Hayes M, et al. Stroke severity in atrial fibrillation. Stroke 1996;27:1760–4.

6. Kirchhoff P, Benussi S, Kotecha D, et al. ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016;37:2893–902.

7. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;383:955–62.

8. Henriksson KM, Farahmand B, Åsberg S, et al. Comparison of cardiovascular risk factors and survival in patients with ischemic or hemorrhagic stroke. Int J Stroke 2012;7:276–81.

9. Grond M, Jauss M, Hamann G, et al. Improved detection of silent atrial fibrillation episodes. Stroke 2014;45:3357–64.

10. Savelieva I, Camm AJ. Clinical relevance of silent atrial fibrillation: prevalence, prognosis, quality of life, and management. J Interv Card Electrophysiol 2000;4:369–82.

11. Friberg L, Hammar N, Rosenqvist M. Stroke in paroxysmal atrial fibrillation: report from the Stockholm cohort of atrial fibrillation. Eur Heart J 2010;31:967–75.

12. Vanassche T, Lauw MN, Eikelboom JW, et al. Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6963 aspirin-treated patients in ACTIVE-A and AVERROES. Eur Heart J 2015;36:281–8.

13. Thijs V. Atrial fibrillation detection: fishing for an irregular heartbeat before and after stroke. Stroke 2017;48:2671–7.

14. Jauch EC, Saver JL, Adams HP, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American heart Association/ American stroke association. Stroke 2013;44:870–947.

15. Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American heart Association/American stroke association. Stroke 2014;45:2160–236.

16. Freedman B, Camm J, Calkins H, et al. Screening for atrial fibrillation: a report of the AF-SCREEN international collaboration. Circulation 2017;135:1851–67.

17. Sanna T, Diener HC, Passman RS, et al. Crystal AF Investigators. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med 2014;370:2478–86.

18. Dimitropoulos A, Sawyer LM, Lip GYH, et al. Cost-Effectiveness of an insertable cardiac monitor to detect atrial fibrillation in patients with cryptogenic stroke. Int J Stroke 2016;11:302–12.

19. Magnusson P, Koyi H, Mattsson G. A protocol for a prospective observational study using chest and thumb ECG: transient ECG assessment in stroke evaluation (tease) in Sweden. BMJ Open 2018;8:e019933.

20. Insulander P, Carnlöf C, Schenck-Gustafsson K, et al. Device profile of the Coala heart monitor for remote monitoring of the heart rhythm: overview of its efficacy. Expert Rev Med Devices 2020;17:159–65.

21. Doliwa Seboecinski P, Rothe E, Frykman Kull V, Kull F V, et al. Improved screening for silent atrial fibrillation after ischaemic stroke. Europace 2012;14:1112–6.

22. Poulsen MB, Binici Z, Dominguez H, et al. Performance of short ECG recordings twice daily to detect paroxysmal atrial fibrillation in stroke and transient ischemic attack patients. Int J Stroke 2017;12:192–6.

23. Gladstone DJ, Spring M, Dorian P, et al. Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med 2014;370:2467–77.

24. Orrsjö G, Cederin B, Bertholds E, et al. Screening of paroxysmal atrial fibrillation after ischemic stroke: 48-hour Holter monitoring versus prolonged intermittent ECG recording. ISRN Stroke 2014:1–6.

25. Tung CE, Su D, Turakhia MP, et al. Diagnostic yield of extended cardiac patch monitoring in patients with stroke or TIA. Front Neurol 2014;5:266.

26. Svennberg E, Engdahl J, Al-Khairi F, et al. Mass screening for untreated atrial fibrillation: the STROKESTOP study. Circulation 2015;131:2176–84.

27. Halcox JPJ, Wareham K, Cardew A, et al. Assessment of remote heart rhythm sampling using the AliveCor heart monitor to screen for atrial fibrillation: the REHEARSE-AF study. Circulation 2017;136:1784–94.

28. Berge T, Brynildsen J, Larsen HKN, et al. Systematic screening for atrial fibrillation in a 65-year-old population with risk factors for stroke; data from the Akershus cardiac examination 1950 study. Europace 2018;20:299–305.

29. Rosenfeld LE, Amin AN, Hsu JC, et al. The heart rhythm Society/ American College of physicians atrial fibrillation screening and education initiative. Heart Rhythm 2019;16:e59–65.

30. Proietti M, Mairese GH, Goethals P, et al. A population screening programme for atrial fibrillation: a report from the Belgian heart rhythm week screening programme. Europace 2016;18:euw069–86.

31. Tieleman RG, Plantinga Y, Rinkes D, et al. Improved monitoring of hospital detection of silent atrial fibrillation episodes. Scand Cardiovasc J 2009;43:163–8.

32. Sposato LA, Cipriano LE, Saposnik G, et al. Systematic screening for atrial fibrillation after ischemic stroke or transient ischaemic attack: a systematic review and meta-analysis. Lancet Neurol 2015;14:377–87.

33. Labban TCA, Camm AJ. Patient associations as stakeholders: a valuable partner for facilitating access to therapy. Europace 2011;13 Suppl 2:i21–4.